Ann: Quarterly Activity Report & Appendix 4C - 31 December 2020, page-9

@danhoff
Yup, agreed. Sales + rev continue to build up...this 4C still seems like its in the 'interim/grey' period of manufacturing scale-up moving into place VS multiple sales avenues/approvals + deliveries lining up for 2HFY21 (Ag bonus kits + Ab-HIV-FebriDx-other OEM kits)

All in all, company hasn't gone backward since last report (always a risk at newbie level). Even on this bare minimum rev growth $, its still projecting to deliver more than FY20 annual rev (but not enough of course to double SP if it only achieves bare minimum this year).

So, with the ~1.6m units/mth production track + all the various types of tests in play...I am content. I am reasonably expecting next 4C to show much, much more sales + profits being realised from all these partnerships.